| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ANO1 |
| Uniprot No | Q5XXA6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 806-892aa |
| 氨基酸序列 | SFTSDFIPRLVYLYMYSKNGTMHGFVNHTLSSFNVSDFQNGTAPNDPLDLGYEVQICRYKDYREPPWSENKYDISKDFWAVLAARLA |
| 预测分子量 | 17.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ANO1(TMEM16A)重组蛋白研究的3篇代表性文献，涵盖结构解析、功能机制及抑制剂筛选方向：
1. **文献名称**：Structure of the human calcium-activated chloride channel TMEM16A
**作者**：Paulino et al. (2017)
**摘要**：通过冷冻电镜解析了人源ANO1重组蛋白的闭合态三维结构，揭示了钙离子结合位点及氯离子传导路径，为研究其门控机制提供了结构基础。
2. **文献名称**：Activation mechanism of the calcium-activated chloride channel TMEM16A revealed by cryo-EM
**作者**：Dang et al. (2017)
**摘要**：利用重组ANO1蛋白进行冷冻电镜分析，捕获了钙离子结合后通道开放的构象变化，阐明了钙依赖性的通道激活分子机制。
3. **文献名称**：Identification of a potent pharmacological inhibitor of the calcium-activated chloride channel TMEM16A
**作者**：Seo et al. (2016)
**摘要**：基于HEK293细胞表达的ANO1重组蛋白进行高通量筛选，发现小分子抑制剂Ani9能特异性阻断其氯离子电流，为相关疾病治疗提供候选药物。
以上文献均聚焦于重组ANO1蛋白的实验体系，分别从结构生物学、功能机制和药物开发角度推进了对该通道的理解。
ANO1 (Anoctamin 1), also known as TMEM16A, is a calcium-activated chloride channel (CaCC) protein encoded by the *ANO1* gene. It belongs to the anoctamin family, which comprises 10 members (ANO1-ANO10) involved in ion transport and lipid scrambling. Structurally, ANO1 consists of 10 transmembrane domains with intracellular N- and C-termini, forming a homodimeric channel. Its activation relies on elevated intracellular Ca²⁺ levels, enabling chloride ion flux across cell membranes, which regulates membrane potential, fluid secretion, and cellular excitability.
First identified in 2008. ANO1 is widely expressed in epithelial tissues, smooth muscle, and sensory neurons. It plays critical roles in physiological processes such as airway mucus secretion, gastrointestinal motility, and nociception. Dysregulation of ANO1 is linked to pathologies including cystic fibrosis (as a compensatory chloride channel), hypertension (via vascular smooth muscle contraction), and cancer. Overexpression of ANO1 has been observed in multiple carcinomas (e.g., breast, head/neck, gastrointestinal), where it promotes proliferation, migration, and metastasis.
Recombinant ANO1 proteins are engineered using expression systems (e.g., HEK293. insect cells) for functional studies and drug discovery. These purified proteins enable structural analysis (e.g., cryo-EM studies revealing Ca²⁺-binding sites), electrophysiological characterization, and high-throughput screening of modulators. Small-molecule inhibitors (e.g., T16Ainh-A01. CaCCinh-A01) and activators targeting ANO1 are under investigation for therapeutic applications in cystic fibrosis, hypertension, and cancer. Challenges include achieving isoform specificity due to high homology within the anoctamin family and optimizing pharmacokinetic properties for clinical translation.
×
